 "Lupin launches generic oral contraceptive tablets in US")
Drug firm Lupin has launched its generic oral contraceptive Norgestimate and ethinyl estradiol tablets in the American market after receiving nod from the US health regulator.
Company's subsidiary "Lupin Pharmaceuticals Inc has launched its Norgestimate and ethinyl estradiol tablets USP, 0.18 mg / 0.035 mg, 0.215 mg / 0.035 mg and 0.25 mg / 0.035 mg having received an approval from the United States Food and Drug Administration (USFDA)...," Lupin said.
The USFDA had earlier given approval to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho Tri-Cyclen tablets in the same strengths, it added.
"Ortho Tri-Cyclen had US sales of $177.6 million according to (IMS MAT March 2016)," Lupin said.
The tablets are indicated to prevent pregnancy, it added.
Mumbai-based Lupin manufactures a wide range of branded & generic formulations, biotechnology products and APIs.
Shares of Lupin on Wednesday closed at Rs 1,713.60 per scrip on BSE, up 1.37% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%